Cell and extracellular vesicle therapies for AKI in critical care: clinical translation, organ-support integration, and lessons learned - Takeaways - MDSpire

Cell and extracellular vesicle therapies for AKI in critical care: clinical translation, organ-support integration, and lessons learned

  • By

  • Amankeldi A. Salybekov

  • Aiman Kinzhebay

  • Aina Zhanymbetova

  • Shuzo Kobayashi

  • July 9, 2026

  • 0 min

Share

  • 1

    Acute kidney injury (AKI) affects up to 50% of ICU patients, significantly increasing morbidity and mortality despite renal replacement therapy advancements.

  • 2

    Current management of AKI is largely supportive and does not address the underlying biological mechanisms driving inflammation and microvascular dysfunction.

  • 3

    Regenerative approaches using mesenchymal stromal cells (MSCs) and extracellular vesicles (EVs) aim to promote renal recovery beyond conventional organ support.

  • 4

    Early clinical trials of MSCs and EVs in AKI populations have shown safety but limited efficacy, likely due to AKI heterogeneity and insensitive endpoints.

  • 5

    Future progress in AKI treatment requires phenotype-enriched enrollment, biomarker-guided therapeutic windows, and kidney-specific endpoints.

Original Source(s)

Cell and extracellular vesicle therapies for AKI in critical care: clinical translation, organ-support integration, and lessons learned

  • by Amankeldi A. Salybekov, Aiman Kinzhebay, Aina Zhanymbetova, Shuzo Kobayashi

  • July 9, 2026

Related Content

First application of whole blood exchange–lymphoplasmapheresis combined transfusion for restoring immune homeostasis of ceftriaxone-induced hemolytic crisis: a case report

Sex Differences in Long-Term Overall and Cause-Specific Mortality in Patients With Cirrhosis

Predicting propofol requirements in advanced gastrointestinal endoscopy: a validated model incorporating age and comorbidity index